Moderna, COVID-19
COVID-19 2024 fall guide: Everything Canadians should know about new Moderna vaccine, current variants and more
NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in the fall of 2024." The organization recommends a six-month interval between COVID vaccines, "with a minimum of three months from the last dose."
Moderna Stock Jumps on Canadian Government's Approval of Updated COVID-19 Vaccine
The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last month, the U.S. Food and Drug Administration also gave approval for the vaccine, as well as updated shots from Pfizer ( PFE) and BioNTech ( BNTX ).
Moderna Receives Health Canada Approval For Updated COVID-19 Vaccine Targeting KP.2 Variant Of SARS-COV-2 For Ages Six Months And Older
SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians
FDA OKs third dose for Pfizer and Moderna Covid-19 vaccines
These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing organisations (CMOs) (see BIO 2021: mRNA Vaccine Booster Shots for Covid-19 and Increasing Uptake Will Offer CMOs Lucrative Opportunities,
Moderna Shares Rise on Canada Government Approval of Updated Covid-19 Vaccine
Shares of Moderna rose after the company said that the government of Canada authorized its updated Covid-19 vaccine, joining the U.S. in the approval. The stock was up 4.5% at $72.28 in Tuesday afternoon trading, becoming the best performing stock of the S&P 500 and Nasdaq 100. The stock has, however, dropped 26% since the beginning of the year.
Moderna's updated COVID-19 vaccine for 2024-25 approved in Canada
Health Canada authorized Moderna's updated COVID-19 vaccine on Tuesday to roll out in fall and winter immunization campaigns.
Moderna stock plunges nearly 20% as company reports poor COVID-19 vaccine sales and cuts to research plans
Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...
Moderna to cut $1.1 billion in costs and launch 10 new products by 2027 as it charts post-Covid future
Moderna is deprioritizing certain parts of its pipeline, which involves pausing work on some products and scrapping others.
Nasdaq4d
Down More Than 50%, Is It Time to Buy Moderna Stock as the Biotech Charts a New Post-COVID Path?
Moderna Therapeutics (NASDAQ: MRNA) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine.
COVID variant XEC seeing rapid growth across globe and the U.S. Here's what to know
A new COVID variant XEC is spreading rapidly worldwide and making its way through the U.S. Here's what you need to know.